酪氨酸激酶抑制剂和Mepolizumab在慢性髓性白血病伴嗜酸性粒细胞增多症继发哮喘中的联合应用。

Q2 Medicine Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry Pub Date : 2021-01-01 DOI:10.2174/1871523020999210820091109

Antonio Gidaro, Emanuele Salvi, Maria Cristina Carraro, Roberta Simona Rossi, Roberto Castelli

{"title":"酪氨酸激酶抑制剂和Mepolizumab在慢性髓性白血病伴嗜酸性粒细胞增多症继发哮喘中的联合应用。","authors":"Antonio Gidaro, Emanuele Salvi, Maria Cristina Carraro, Roberta Simona Rossi, Roberto Castelli","doi":"10.2174/1871523020999210820091109","DOIUrl":null,"url":null,"abstract":"Introduction: Asthma and hypereosinophilia have been treated with different therapeutics in the past. Some of them appear to be more effective in symptoms resolution and decreasing eosinophilic count.Case presentation: We report here an unusual case of asthma with hypereosinophilia secondary to Chronic Myeloid Leukemia (CML) with high prevalence of eosinophilic infiltrate, treated simultaneously with an anti-IL-5 antibody (Mepolizumab) and Tyrosine-kinase Inhibitors (TKI: Imatinib and Bosutinib) for three years. The patient showed a promising reduction of pulmonary exacerbations and good control of CML without developing side effects.Conclusion: We hope that this finding could inspire further studies on the efficacy and safety of the concomitant use of anti-IL-5 and TKI.","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":"20 4","pages":"389-393"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Concomitant use of Tyrosine-Kinase Inhibitor and Mepolizumab in Asthma Secondary to Chronic Myeloid Leukemia with Hypereosinophilia.\",\"authors\":\"Antonio Gidaro, Emanuele Salvi, Maria Cristina Carraro, Roberta Simona Rossi, Roberto Castelli\",\"doi\":\"10.2174/1871523020999210820091109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Asthma and hypereosinophilia have been treated with different therapeutics in the past. Some of them appear to be more effective in symptoms resolution and decreasing eosinophilic count.Case presentation: We report here an unusual case of asthma with hypereosinophilia secondary to Chronic Myeloid Leukemia (CML) with high prevalence of eosinophilic infiltrate, treated simultaneously with an anti-IL-5 antibody (Mepolizumab) and Tyrosine-kinase Inhibitors (TKI: Imatinib and Bosutinib) for three years. The patient showed a promising reduction of pulmonary exacerbations and good control of CML without developing side effects.Conclusion: We hope that this finding could inspire further studies on the efficacy and safety of the concomitant use of anti-IL-5 and TKI.\",\"PeriodicalId\":35423,\"journal\":{\"name\":\"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry\",\"volume\":\"20 4\",\"pages\":\"389-393\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871523020999210820091109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871523020999210820091109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

简介:哮喘和嗜酸性粒细胞增多症在过去有不同的治疗方法。其中一些似乎在缓解症状和减少嗜酸性粒细胞计数方面更有效。病例介绍:我们在此报告一例罕见的哮喘伴嗜酸性粒细胞增多继发于慢性髓性白血病(CML)，伴嗜酸性粒细胞浸润，同时使用抗il -5抗体(Mepolizumab)和酪氨酸激酶抑制剂(TKI:伊马替尼和博苏替尼)治疗三年。患者表现出有希望减少肺部恶化和良好的控制CML没有发展的副作用。结论:我们希望这一发现能够启发进一步研究抗il -5和TKI合用的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Concomitant use of Tyrosine-Kinase Inhibitor and Mepolizumab in Asthma Secondary to Chronic Myeloid Leukemia with Hypereosinophilia.

Introduction: Asthma and hypereosinophilia have been treated with different therapeutics in the past. Some of them appear to be more effective in symptoms resolution and decreasing eosinophilic count.

Case presentation: We report here an unusual case of asthma with hypereosinophilia secondary to Chronic Myeloid Leukemia (CML) with high prevalence of eosinophilic infiltrate, treated simultaneously with an anti-IL-5 antibody (Mepolizumab) and Tyrosine-kinase Inhibitors (TKI: Imatinib and Bosutinib) for three years. The patient showed a promising reduction of pulmonary exacerbations and good control of CML without developing side effects.

Conclusion: We hope that this finding could inspire further studies on the efficacy and safety of the concomitant use of anti-IL-5 and TKI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.30

自引率

0.00%

发文量

期刊介绍： Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new anti-inflammatory & anti-allergy agents. Publishing a series of timely in-depth reviews written by leaders in the field covering a range of current topics, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in the field.